Rave RTSM Direct-to-Patient

By Medidata

Medidata RTSM Direct-to-Patient (DtP) offers flexible solutions for various drug dispensation scenarios, going beyond COVID-19 disruptions to address fundamental patient burden issues in drug development. This system allows sites to customize visit schedules, determining whether to dispense from site stock or ship directly to patients. With real-time visibility into the full lifecycle of shipments and dispensations, Medidata ensures full accountability while protecting patient privacy. Whether fully decentralized or using a hybrid model, DtP supports seamless transitions between virtual and physical sites. Download the fact sheet to learn how Medidata can enhance your trial's flexibility and efficiency.

Enter your details to receive the free white paper:

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.